Results 61 to 70 of about 141 (84)
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. [PDF]
Cao J +14 more
europepmc +1 more source
Thermogenesis in Adipose Tissue: Adrenergic and Non-Adrenergic Pathways. [PDF]
Hossain MA, Poojari A, Rabiee A.
europepmc +1 more source
Impact of secretin receptor homo-dimerization on natural ligand binding. [PDF]
Harikumar KG +5 more
europepmc +1 more source
Altered Intracellular Trafficking as a Mechanism for Prolonged Duration of G Protein-Coupled Receptor Activation. [PDF]
Kim TW +7 more
europepmc +1 more source
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application. [PDF]
Bae JH.
europepmc +1 more source
Cholesterol-dependent dynamic changes in the conformation of the type 1 cholecystokinin receptor affect ligand binding and G protein coupling. [PDF]
Harikumar KG +13 more
europepmc +1 more source
What is the pipeline for future medications for obesity? [PDF]
Melson E +3 more
europepmc +1 more source
Dual amylin and calcitonin receptor agonists (DACRAs) are therapeutic candidates in the treatment of obesity with beneficial effects on weight loss superior to suppression of food intake. Hence, suggesting effects on energy expenditure by possibly targeting mitochondria in metabolically active tissue.Male rats with HFD-induced obesity received a DACRA,
Morten Karsdal +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Physiology - Endocrinology and Metabolism, 2016
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake and body weight. KBP-088 and davalintide were tested
Morten Karsdal +2 more
exaly +3 more sources
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake and body weight. KBP-088 and davalintide were tested
Morten Karsdal +2 more
exaly +3 more sources

